| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S1386-6532(00)00139-6 |
| P698 | PubMed publication ID | 11166661 |
| P2093 | author name string | Boelaert JR | |
| Savarino A | |||
| Gennero L | |||
| Sperber K | |||
| P2860 | cites work | Desferrioxamine and HIV | Q28322661 |
| Inhibition of Human Immunodeficiency Virus Infectivity by Chloroquine | Q28323345 | ||
| Processing of the structural proteins of human immunodeficiency virus type 1 in the presence of monensin and cerulenin | Q28361162 | ||
| Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication | Q28368051 | ||
| Chloroquine exerts an additive in vitro anti-HIV type 1 effect when associated with didanosine and hydroxyurea | Q28373409 | ||
| Inhibitors of human immunodeficiency virus integrase | Q28378683 | ||
| Uptake of chloroquine and hydroxychloroquine by human blood leucocytes in vitro: relation to cellular concentrations during antirheumatic therapy | Q33557174 | ||
| Iron metabolism and HIV infection: reciprocal interactions with potentially harmful consequences? | Q33787919 | ||
| Chloroquine induces human macrophage killing of Histoplasma capsulatum by limiting the availability of intracellular iron and is therapeutic in a murine model of histoplasmosis | Q34137889 | ||
| Chloroquine inhibits the intracellular multiplication of Legionella pneumophila by limiting the availability of iron. A potential new mechanism for the therapeutic effect of chloroquine against intracellular pathogens | Q34226242 | ||
| Chloroquine serum concentration and side effects: Evidence for dose-dependent kinetics | Q40700565 | ||
| Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine | Q41152773 | ||
| Inhibition of HIV-1 Tat-mediated transactivation by quinacrine and chloroquine | Q41168935 | ||
| Thiamine disulfide as a potent inhibitor of human immunodeficiency virus (type-1) production | Q41427232 | ||
| Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes | Q41581307 | ||
| Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. | Q41927429 | ||
| Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. | Q41932765 | ||
| Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication | Q42282677 | ||
| Antiretroviral treatment | Q42538941 | ||
| Reduction and loss of the iron center in the reaction of the small subunit of mouse ribonucleotide reductase with hydroxyurea | Q72551680 | ||
| Hydroxyurea and HIV: 5 years later--from antiviral to immune-modulating effects | Q78180295 | ||
| P433 | issue | 3 | |
| P921 | main subject | chloroquine | Q422438 |
| P304 | page(s) | 131-135 | |
| P577 | publication date | 2001-02-01 | |
| P1433 | published in | Journal of Clinical Virology | Q15759726 |
| P1476 | title | The anti-HIV-1 activity of chloroquine | |
| P478 | volume | 20 |
| Q37274730 | Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice |
| Q38291146 | Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action? |
| Q41921243 | Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy |
| Q95604154 | Azithromycin and ciprofloxacin have a chloroquine-like effect on respiratory epithelial cells |
| Q35172448 | BCA2/Rabring7 targets HIV-1 Gag for lysosomal degradation in a tetherin-independent manner |
| Q91945830 | COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies |
| Q33617999 | Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model |
| Q36309457 | Chronic use of chloroquine disrupts the urine concentration mechanism by lowering cAMP levels in the inner medulla |
| Q54218397 | Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. |
| Q35195445 | Deletion of the highly conserved N-glycan at Asn260 of HIV-1 gp120 affects folding and lysosomal degradation of gp120, and results in loss of viral infectivity |
| Q39964308 | Development and in vitro evaluation of chloroquine gels as microbicides against HIV-1 infection |
| Q34042632 | Ebola virus (EBOV) infection: Therapeutic strategies |
| Q30359528 | Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+ T-lymphocytes. |
| Q33973620 | Effects of chloroquine on viral infections: an old drug against today's diseases? |
| Q36127686 | Expanding the frontiers of existing antiviral drugs: possible effects of HIV-1 protease inhibitors against SARS and avian influenza |
| Q30244058 | Filovirus proteins for antiviral drug discovery: A structure/function analysis of surface glycoproteins and virus entry |
| Q39963331 | Gold(I) complex of 1,1'-bis(diphenylphosphino) ferrocene-quinoline conjugate: a virostatic agent against HIV-1. |
| Q35153151 | HIV transmission through breastfeeding: problems and prevention |
| Q34714438 | HIV-1/AIDS and the control of other infectious diseases in Africa |
| Q41945241 | Hydroxychloroquine potentiates Fas-mediated apoptosis of rheumatoid synoviocytes. |
| Q35148912 | Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery |
| Q37827403 | Hydroxychloroquine: from malaria to autoimmunity |
| Q41914491 | Hypothesis links emergence of chloroquine-resistant malaria and other intracellular pathogens and suggests a new strategy for treatment of diseases caused by intracellular parasites |
| Q41913526 | In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine |
| Q35191410 | Influence of quinacrine and chloroquine on the in vitro 3'-azido-3'-deoxythymidine antiretroviral effect. |
| Q41942176 | Inhibition of betanodavirus infection by inhibitors of endosomal acidification |
| Q35673457 | Lack of protection against ebola virus from chloroquine in mice and hamsters |
| Q37245300 | Malaria and HIV co-infection in pregnancy in sub-Saharan Africa: impact of treatment using antimalarial and antiretroviral agents |
| Q35880187 | Maternal malaria and perinatal HIV transmission, western Kenya |
| Q41923063 | Natural history of five children with surfactant protein C mutations and interstitial lung disease. |
| Q90327245 | New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? |
| Q99616870 | Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives |
| Q24799086 | Quinine sulfate and bacterial invasion |
| Q89906102 | Relationship between placenta malaria and mother to child transmission of HIV infection in pregnant women in South East Nigeria |
| Q40045378 | Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review |
| Q38749963 | Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection |
| Q37418140 | Serious Non-AIDS events: Immunopathogenesis and interventional strategies |
| Q40122517 | Synthesis and in vitro cytotoxicity evaluation of 4-aminoquinoline derivatives |
| Q39360987 | Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases |
| Q92633499 | The Use of Antimalarial Drugs against Viral Infection |
| Q31884618 | The potential place of chloroquine in the treatment of HIV-1-infected patients |
Search more.